Quick Answer
Outlook Therapeutics, Inc. reported Long-Term Debt of $50.3 thousand for fiscal year 2019.
Outlook Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2019 | $50.3K | -48.9% |
| 2018 | $98.5K | -34.8% |
| 2017 | $151.1K | -93.2% |
| 2016 | $2.23M | -23.6% |
| 2015 | $2.92M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2019 | $62.9K | -43.6% | -16.3% |
| March 31, 2019 | $75.1K | -41.3% | -13.7% |
| December 31, 2018 | $86.9K | -39.4% | -11.7% |
| September 30, 2018 | $98.5K | -34.8% | -11.7% |
| June 30, 2018 | $111.5K | -32.4% | -12.7% |
| March 31, 2018 | $127.8K | -28.3% | -10.9% |
| December 31, 2017 | $143.5K | -25.0% | -5.0% |
| September 30, 2017 | $151.1K | -93.2% | -8.4% |
- Outlook Therapeutics, Inc. showed a decrease of -48.9% in Long-Term Debt compared to the prior fiscal year.
- Over the 2015–2019 period, Outlook Therapeutics, Inc.’s long-term debt has declined by 98.3% (from $2.92 million to $50.3 thousand).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on December 19, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: